Summary
The atrophogenic potential of medium-potent topical glucocorticoids is still controversial. In a double-blind controlled trial 24 healthy volunteers either applied 0.25% prednicarbate cream or the corresponding vehicle to one and 0.1% betamethasone-17-valerate cream or 0.05% clobetasol-17-propionate cream to the other forearm twice daily. Skin thickness was regularly assessed during the six week period of application and for further three weeks thereafter, using both the B- and A-mode of a 20 MHz ultrasound scanner.
Both betamethasone-17-valerate and clobetasol-17-propionate cream significantly reduced skin thickness as compared to cream base while prednicarbate cream did not.
Given that 0.1% betamethasone-17-valerate- and 0.25% prednicarbate cream are reported to be about equipotent in the treatment of atopic eczema the latter preparation shows an increased ratio between its desired anti-inflammatory and its unwanted atrophogenic effect.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Epstein NN, Epstein WL, Epstein JH (1963) Atrophic striae in patients with inguinal intertrigo. Arch Dermatol 87: 450–457
Takeda K, Arase S, Takahashi S (1988) Side effects of topical corticoids and their prevention. Drugs 36 [Suppl 5]: 15–23
Töpert M (1988) Perspectives in corticosteroid research. Drugs 36 [Suppl 5]: 1–8
Hevert F, Schipp I, Busch B, Rozman T (1989) Kortikosteroid-Ester. Dtsch Derm 37: 678–683
Vogt HJ, Höhler Th (1988) Controlled studies of intraindividual and interindividual design for comparing corticosteroids clinically. In: Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds) Topical corticosteroid therapy. Raven, New York, pp 169–180
Schröpl F, Schubert Ch (1988) Long-term study on local steroids using the example of prednicarbate. In: Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds) Topical corticosteroid therapy. Raven, New York, pp 155–168
Tan C, Marks R, Payne P (1981) Comparison of xeroradiographic and ultrasound detection of corticosteroid induced dermal thinning. J Invest Dermatol 76: 126–128
Dykes PJ, Hill S, Marks R (1988) Assessment of the atrophogenicity potential of corticosteroids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions. In: Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds) Topical Corticosteroid Therapy. Raven, New York, pp 111–118
Lubach D, Grüter M (1988) Vergleichende Untersuchungen über die hautverdünnende Wirkung von Amcinonid and Prednicarbat an unterschiedlichen Körperregionen des Menschen. Akt Dermatol 14; 197–200
Søndergaard J, Serup J, Tikjob G (1986) Ultrasonic A- and B-scanning in clinical and experimental dermatology. Acta Dermatovenerol (Stockh) [Suppl] 120: 76–82
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Korting, H.C., Vieluf, D. & Kerscher, M. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 42, 159–161 (1992). https://doi.org/10.1007/BF00278477
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00278477